Renovos Biologics Welcomes Lisa Ferrara to the Board
Renovos Biologics is excited to announce that Lisa Ferrara, Ph.D., has joined as a Non-Executive Director. With over thirty years of experience in orthopaedic medical device innovation and regulatory strategy, Dr. Ferrara brings extensive expertise that is set to enhance Renovos' mission.
Dr. Ferrara's Responsibilities and Impact
In her new position, Dr. Ferrara will play a crucial role in moving Renovos' leading product, RENOVITE® BMP-2, towards FDA regulatory approval. This product has the potential to transform precision regenerative medicine with its unique delivery methods.
What is RENOVITE® BMP-2?
RENOVITE® is an advanced synthetic, biodegradable nanoclay carrier that serves as a novel therapeutic delivery platform, specifically crafted for regenerative medicine applications. Its design focuses on optimizing the retention of Bone Morphogenetic Protein 2 (BMP-2), which increases the chances of successful bone fusion, especially during delicate spinal procedures.
A Diverse Background
Dr. Ferrara has a distinguished history as a managing partner of Hypoid Ventures, LLC, and is the founder of two thriving companies dedicated to evaluating orthopaedic medical devices. Her deep insights into the field will enhance the board’s ability to navigate the complexities of medical innovation and regulatory challenges.
Academic Achievements and Professional Milestones
Dr. Ferrara boasts an impressive academic portfolio, with over 60 journal publications and contributions to 26 book chapters. She previously founded the Spine Research Laboratory at the Cleveland Clinic Foundation, reflecting her dedication to advancing healthcare technology. Additionally, her numerous patents further solidify her role as a thought leader in the industry.
Preparing for Growth and IPO
Having achieved Breakthrough Device Designation from the FDA for RENOVITE® BMP-2, Renovos Biologics is positioned for significant growth. With Dr. Ferrara's guidance, the company is focused on advancing its work towards critical first-in-human trials and beyond, paving the way for the launch of innovative therapies.
Perspectives from the Board on Dr. Ferrara's Appointment
Dr. Agnieszka Janeczek, Chief Executive Officer of Renovos Biologics, expressed her excitement about Dr. Ferrara joining the team, emphasizing that her regulatory and industry expertise is vital for strengthening Renovos' orthobiologic programs. This appointment highlights Renovos' commitment to making impactful breakthroughs in regenerative therapies.
About Renovos Biologics
Renovos Biologics specializes in regenerative medicine, focusing on its proprietary RENOVITE® synthetic nanoclay for medical applications. This technology emerged from research conducted at the University of Southampton and signifies important advancements in regenerative medicine, particularly in orthobiologics. RENOVITE® is designed to deliver therapeutic agents more effectively and safely, targeting specific areas where they are most needed.
Frequently Asked Questions
What does Renovos Biologics focus on?
Renovos Biologics is known for its pioneering work in regenerative medicine, especially its synthetic nanoclay technology aimed at orthobiologic applications.
Who is Dr. Lisa Ferrara?
Lisa Ferrara, Ph.D., is a highly experienced professional in orthopaedic devices, recently appointed as a Non-Executive Director at Renovos Biologics.
Can you explain RENOVITE® BMP-2?
RENOVITE® BMP-2 is the lead product from Renovos, designed to improve the delivery and retention of Bone Morphogenetic Protein 2, enhancing bone fusion outcomes in medical procedures.
What advantages does RENOVITE® technology provide?
RENOVITE® technology facilitates targeted delivery of therapeutic agents, improving effectiveness while minimizing potential side effects in regenerative medicine treatments.
What are Renovos Biologics' upcoming plans?
Renovos Biologics is looking to conduct first-in-human trials for RENOVITE® BMP-2 and continue expanding its portfolio of innovative regenerative medicine therapies.
